Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Lancet Oncol. 2016 Dec 7;18(1):52–62. doi: 10.1016/S1470-2045(16)30631-3

Figure 2. Stromal TILs and survival.

Figure 2

Kaplan-Meier curves are stratified by mean stromal TIL value (≤20% vs >20%). All analyses were done in the intention-to-treat population of patients with evaluable TILs. Plots show progression-free survival in the whole cohort (A) and in patients grouped by stromal TIL value and treatment group (all patients also received trastuzumab and docetaxel; B), and overall survival in the whole cohort (C) and in patients grouped by stromal TIL value and treatment group (D). HR=hazard ratio for patients with >20% TILs vs those with ≤20% TILs. NR=not reached. TIL= tumour-infiltrating lymphocyte.